Since the appearance, in 1938. of favorable reports1 on the use of sulfapyridine (2-[paraaminobenzenesulfonamido]-pyridine) in the treatment of pneumococcic pneumonia, attention has been focused on this substance. Agreement on its usefulness has been general, but little mention has been made of the serious toxic manifestations which may attend its use. It is chiefly by reason of the latter fact that we are making a report on a small series of cases.
SELECTION OF CASES
Sulfapyridine became available in this hospital in October 1938,1a at a time when we were still engaged in evaluating antipneumococcus rabbit serum in the therapy of pneumonia. This work was continued until mid-December. Until that time, therefore, patients with pneumonia were divided into three groups: those who were being treated with serum, those who were treated with sulfapyridine and controls. This accounts for the small number of patients treated with sulfapyridine up to that
DETWEILER HK, KINSEY HI, HURST W, FEASBY WR. TREATMENT OF PNEUMONIA WITH SULFAPYRIDINE: OBSERVATIONS ON TOXIC REACTIONS. Arch Intern Med (Chic). 1940;65(6):1144–1157. doi:10.1001/archinte.1940.00190120061006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: